{"hands_on_practices": [{"introduction": "The Gα subunit of a heterotrimeric G protein functions as a precisely-regulated molecular switch, with its GTP-bound \"on\" state lasting for a finite period. This duration is critical as it dictates the timescale of downstream signaling. This practice delves into the kinetics of this molecular timer, challenging you to derive the effective lifetime of the active Gα-GTP state when it is subject to two parallel deactivation pathways: its own intrinsic GTPase activity and accelerated hydrolysis by a Regulator of G protein Signaling (RGS) protein [@problem_id:2803583]. By applying first principles of probability, you will see how competing processes combine to shape the dynamics of a fundamental signaling node.", "problem": "A guanine nucleotide-binding G protein-coupled receptor (GPCR) activates a heterotrimeric G protein by promoting guanosine triphosphate (GTP) binding to the G$\\alpha$ subunit. The active G$\\alpha$-GTP state deactivates by GTP hydrolysis. In the absence of any catalyst, this hydrolysis is well described as a first-order process with rate constant $k_{\\mathrm{GTP}}$. A Regulator of G protein Signaling (RGS) protein binds and catalyzes GTP hydrolysis. Under conditions where RGS binding/unbinding equilibrates rapidly relative to hydrolysis, the RGS-mediated hydrolysis can be modeled as a pseudo-first-order process with effective rate constant $k_{\\mathrm{RGS}} = k_{\\mathrm{acc}}[{\\mathrm{RGS}}]$, where $k_{\\mathrm{acc}}$ is a bimolecular acceleration constant and $[{\\mathrm{RGS}}]$ is the free RGS concentration that remains approximately constant because RGS is in excess.\n\nStarting only from the definition of first-order decay as a memoryless process and the rules of probability applied over an infinitesimal time interval, derive the effective deactivation rate constant $k_{\\mathrm{eff}}$ that governs loss of G$\\alpha$-GTP activity when both the intrinsic and the RGS-mediated hydrolysis pathways operate concurrently and independently. Then obtain the mean active lifetime $\\tau$ of G$\\alpha$-GTP from your expression.\n\nFinally, evaluate $\\tau$ numerically for $k_{\\mathrm{GTP}} = 0.06\\,\\mathrm{s}^{-1}$, $k_{\\mathrm{acc}} = 2.0\\,\\mathrm{s}^{-1}\\,\\mu\\mathrm{M}^{-1}$, and $[{\\mathrm{RGS}}] = 0.45\\,\\mu\\mathrm{M}$. Express the active lifetime in seconds and round your answer to three significant figures.", "solution": "The problem as stated is scientifically grounded, well-posed, and contains sufficient information for a unique solution. It is a valid problem in biochemical kinetics.\n\nThe problem requires a derivation of the effective deactivation rate constant, $k_{\\mathrm{eff}}$, for a G$\\alpha$-GTP protein that can be inactivated by two concurrent and independent first-order pathways: an intrinsic pathway with rate constant $k_{\\mathrm{GTP}}$ and an RGS-catalyzed pathway with a pseudo-first-order rate constant $k_{\\mathrm{RGS}}$. The derivation must be based on probabilistic principles over an infinitesimal time interval $dt$.\n\nLet $S(t)$ be the probability that a single G$\\alpha$-GTP molecule, active at time $t=0$, remains active at a later time $t$. This is the survival function, with the initial condition $S(0) = 1$. A first-order decay process is memoryless, which implies that the probability of decay within a future time interval is independent of its past history.\n\nConsider an infinitesimal time interval from $t$ to $t+dt$. The probability of decay via the intrinsic pathway during this interval, given the molecule is active at time $t$, is proportional to $dt$. We define this probability as $p_{\\mathrm{GTP}} = k_{\\mathrm{GTP}} dt$. Similarly, the probability of decay via the RGS-mediated pathway during the same interval is $p_{\\mathrm{RGS}} = k_{\\mathrm{RGS}} dt$.\n\nThe problem states that the two pathways operate independently. Therefore, the probability that the molecule survives the interval $dt$ is the probability that it does *not* decay by the intrinsic pathway AND it does *not* decay by the RGS pathway. The probability of not decaying via the intrinsic pathway is $(1 - p_{\\mathrm{GTP}})$, and the probability of not decaying via the RGS pathway is $(1 - p_{\\mathrm{RGS}})$. Due to independence, the total survival probability for the interval $dt$ is the product of these individual probabilities:\n$$\nP(\\text{survival in } dt) = (1 - p_{\\mathrm{GTP}})(1 - p_{\\mathrm{RGS}}) = (1 - k_{\\mathrm{GTP}} dt)(1 - k_{\\mathrm{RGS}} dt)\n$$\nExpanding this expression gives:\n$$\nP(\\text{survival in } dt) = 1 - k_{\\mathrm{GTP}} dt - k_{\\mathrm{RGS}} dt + (k_{\\mathrm{GTP}} k_{\\mathrm{RGS}})(dt)^2\n$$\nAs $dt$ is an infinitesimal quantity, the term containing $(dt)^2$ is of a higher order and can be neglected. This leaves:\n$$\nP(\\text{survival in } dt) \\approx 1 - (k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}}) dt\n$$\nThe probability of the molecule being active at time $t+dt$ is the probability that it was active at time $t$ multiplied by the probability that it survived the subsequent interval $dt$.\n$$\nS(t+dt) = S(t) \\times P(\\text{survival in } dt) = S(t) [1 - (k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}}) dt]\n$$\nRearranging this equation to form a differential yields:\n$$\n\\frac{S(t+dt) - S(t)}{dt} = - (k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}}) S(t)\n$$\nIn the limit as $dt \\to 0$, this becomes the differential equation:\n$$\n\\frac{dS(t)}{dt} = - (k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}}) S(t)\n$$\nThis equation describes a first-order decay process. By comparing it to the general form $\\frac{dS(t)}{dt} = -k_{\\mathrm{eff}} S(t)$, we identify the effective rate constant $k_{\\mathrm{eff}}$ for the combined process as the sum of the individual rate constants:\n$$\nk_{\\mathrm{eff}} = k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}}\n$$\n\nNext, we must obtain the mean active lifetime, $\\tau$, from this expression. The mean lifetime is the expectation value of the time to decay. The probability density function for decay at time $t$, denoted $f(t)$, is related to the survival function $S(t) = \\exp(-k_{\\mathrm{eff}} t)$ by $f(t) = - \\frac{dS(t)}{dt}$.\n$$\nf(t) = - \\frac{d}{dt} \\left( \\exp(-k_{\\mathrm{eff}} t) \\right) = k_{\\mathrm{eff}} \\exp(-k_{\\mathrm{eff}} t)\n$$\nThe mean lifetime $\\tau$ is calculated by integrating $t$ over this probability distribution from $t=0$ to $t=\\infty$:\n$$\n\\tau = \\int_0^{\\infty} t f(t) dt = \\int_0^{\\infty} t k_{\\mathrm{eff}} \\exp(-k_{\\mathrm{eff}} t) dt\n$$\nWe solve this integral using integration by parts, $\\int u dv = uv - \\int v du$. Let $u=t$ and $dv = k_{\\mathrm{eff}} \\exp(-k_{\\mathrm{eff}} t) dt$. Then $du=dt$ and $v = -\\exp(-k_{\\mathrm{eff}} t)$.\n$$\n\\tau = \\left[ -t \\exp(-k_{\\mathrm{eff}} t) \\right]_0^{\\infty} - \\int_0^{\\infty} (-\\exp(-k_{\\mathrm{eff}} t)) dt\n$$\nThe first term evaluates to $0$ at both limits. At the upper limit, $\\lim_{t \\to \\infty} -t \\exp(-k_{\\mathrm{eff}} t) = 0$. At the lower limit, the term is $0$. The integral becomes:\n$$\n\\tau = \\int_0^{\\infty} \\exp(-k_{\\mathrm{eff}} t) dt = \\left[ -\\frac{1}{k_{\\mathrm{eff}}} \\exp(-k_{\\mathrm{eff}} t) \\right]_0^{\\infty} = \\left( 0 \\right) - \\left( -\\frac{1}{k_{\\mathrm{eff}}} \\exp(0) \\right) = \\frac{1}{k_{\\mathrm{eff}}}\n$$\nThus, the mean active lifetime is the reciprocal of the effective rate constant:\n$$\n\\tau = \\frac{1}{k_{\\mathrm{eff}}} = \\frac{1}{k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}}}\n$$\nUsing the given expression for the RGS-mediated rate, $k_{\\mathrm{RGS}} = k_{\\mathrm{acc}}[\\mathrm{RGS}]$, we have:\n$$\n\\tau = \\frac{1}{k_{\\mathrm{GTP}} + k_{\\mathrm{acc}}[\\mathrm{RGS}]}\n$$\nFinally, we evaluate $\\tau$ numerically using the provided values: $k_{\\mathrm{GTP}} = 0.06\\,\\mathrm{s}^{-1}$, $k_{\\mathrm{acc}} = 2.0\\,\\mathrm{s}^{-1}\\,\\mu\\mathrm{M}^{-1}$, and $[\\mathrm{RGS}] = 0.45\\,\\mu\\mathrm{M}$.\nFirst, calculate the RGS-mediated rate constant:\n$$\nk_{\\mathrm{RGS}} = (2.0\\,\\mathrm{s}^{-1}\\,\\mu\\mathrm{M}^{-1}) \\times (0.45\\,\\mu\\mathrm{M}) = 0.90\\,\\mathrm{s}^{-1}\n$$\nNext, calculate the effective rate constant:\n$$\nk_{\\mathrm{eff}} = k_{\\mathrm{GTP}} + k_{\\mathrm{RGS}} = 0.06\\,\\mathrm{s}^{-1} + 0.90\\,\\mathrm{s}^{-1} = 0.96\\,\\mathrm{s}^{-1}\n$$\nThe mean active lifetime is then:\n$$\n\\tau = \\frac{1}{k_{\\mathrm{eff}}} = \\frac{1}{0.96\\,\\mathrm{s}^{-1}} \\approx 1.04166\\dots\\,\\mathrm{s}\n$$\nRounding to three significant figures, the mean active lifetime is $1.04\\,\\mathrm{s}$.", "answer": "$$\n\\boxed{1.04}\n$$", "id": "2803583"}, {"introduction": "Once a G protein is active, it regulates effector enzymes that produce second messengers, and the concentration of these messengers determines the cellular response. This exercise models the dynamics of cyclic AMP (cAMP), a ubiquitous second messenger, by applying the fundamental principle of mass balance. You will construct a simple but powerful ordinary differential equation to describe how the constant production of cAMP by adenylyl cyclase and its first-order degradation by phosphodiesterase establish a stable, steady-state concentration [@problem_id:2803640]. This practice provides a quantitative foundation for understanding how cells maintain signaling homeostasis and how quickly they can respond to changes.", "problem": "A cell expressing a stimulatory G protein-coupled receptor (GPCR) is exposed to a sustained, saturating agonist such that adenylyl cyclase (AC) activity is driven to a constant production rate of cyclic adenosine monophosphate (cAMP). Phosphodiesterase (PDE) degrades cAMP with first-order kinetics. Assume a single, well-mixed compartment of fixed volume with no other sources or sinks of cAMP. Use the following foundational principles:\n- Mass balance: the rate of change of a well-mixed intracellular concentration equals production minus removal.\n- Kinetic assumptions: AC-driven cAMP production proceeds at zero-order rate $k_{\\mathrm{AC}}$ under saturating receptor activation, and PDE-driven cAMP degradation follows first-order kinetics with rate constant $k_{\\mathrm{PDE}}$.\n\nStarting from these principles, derive the governing ordinary differential equation for the cAMP concentration $c(t)$, identify the steady-state concentration $c^{\\ast}$, and determine the dominant time constant $\\tau$ that characterizes the approach to steady state following a small perturbation around $c^{\\ast}$.\n\nGiven $k_{\\mathrm{AC}}=2\\,\\mu\\mathrm{M\\,s^{-1}}$ and $k_{\\mathrm{PDE}}=1\\,\\mathrm{s^{-1}}$, compute the numerical values of $c^{\\ast}$ and $\\tau$. Round your answer to $3$ significant figures. Express $c^{\\ast}$ in $\\mu\\mathrm{M}$ and $\\tau$ in $\\mathrm{s}$.\n\nReport your final answer as a $1\\times 2$ row vector $\\big[c^{\\ast},\\,\\tau\\big]$ in that order. Do not include units inside the vector; units are as specified above.", "solution": "The problem will first be validated against the required criteria.\n\n**Step 1: Extract Givens**\n- System: A cell expressing a stimulatory G protein-coupled receptor (GPCR).\n- Condition: The cell is exposed to a sustained, saturating agonist.\n- Process 1: Adenylyl cyclase (AC) drives a constant production rate of cyclic adenosine monophosphate (cAMP).\n- Process 2: Phosphodiesterase (PDE) degrades cAMP with first-order kinetics.\n- System properties: Single, well-mixed compartment of fixed volume; no other sources or sinks of cAMP.\n- Foundational Principles:\n    - Mass balance: the rate of change of a well-mixed intracellular concentration equals production minus removal.\n    - Kinetic assumptions: AC-driven cAMP production proceeds at zero-order rate $k_{\\mathrm{AC}}$ under saturating receptor activation, and PDE-driven cAMP degradation follows first-order kinetics with rate constant $k_{\\mathrm{PDE}}$.\n- Tasks:\n    1. Derive the governing ordinary differential equation for the cAMP concentration $c(t)$.\n    2. Identify the steady-state concentration $c^{\\ast}$.\n    3. Determine the dominant time constant $\\tau$ that characterizes the approach to steady state following a small perturbation around $c^{\\ast}$.\n    4. Compute numerical values of $c^{\\ast}$ and $\\tau$.\n- Given Constants: $k_{\\mathrm{AC}}=2\\,\\mu\\mathrm{M\\,s^{-1}}$ and $k_{\\mathrm{PDE}}=1\\,\\mathrm{s^{-1}}$.\n- Output requirements: Round the answer to $3$ significant figures. Express $c^{\\ast}$ in $\\mu\\mathrm{M}$ and $\\tau$ in $\\mathrm{s}$. Report as a $1\\times 2$ row vector $[c^{\\ast}, \\tau]$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is assessed for validity.\n- **Scientifically Grounded:** Yes. The problem describes a standard, simplified model of intracellular signaling dynamics, specifically the balance between cAMP synthesis by adenylyl cyclase and its degradation by phosphodiesterase. This model is rooted in fundamental principles of chemical kinetics and mass balance, which are standard tools in systems biology.\n- **Well-Posed:** Yes. The problem statement provides a clear set of assumptions and parameters for deriving and analyzing a first-order linear ordinary differential equation. This type of problem has a unique, stable, and meaningful solution.\n- **Objective:** Yes. The language is precise, quantitative, and free of subjective or ambiguous terminology.\n- **Completeness and Consistency:** Yes. The problem is self-contained. All necessary kinetic laws and parameter values are provided, and there are no internal contradictions.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be constructed.\n\n**Derivation of the Governing Equation**\nWe apply the principle of mass balance. Let $c(t)$ be the concentration of cAMP at time $t$. The rate of change of $c(t)$ is the difference between its production rate and its removal rate.\nThe production of cAMP by adenylyl cyclase is given as a zero-order process with a constant rate $k_{\\mathrm{AC}}$.\nRate of Production $= k_{\\mathrm{AC}}$.\nThe degradation of cAMP by phosphodiesterase is a first-order process, meaning its rate is proportional to the concentration $c(t)$. The rate constant is $k_{\\mathrm{PDE}}$.\nRate of Removal $= k_{\\mathrm{PDE}} c(t)$.\n\nCombining these according to the mass balance principle, we obtain the governing ordinary differential equation (ODE):\n$$\n\\frac{dc(t)}{dt} = k_{\\mathrm{AC}} - k_{\\mathrm{PDE}} c(t)\n$$\n\n**Identification of the Steady-State Concentration**\nAt steady state, the concentration of cAMP no longer changes with time. This condition is defined by $\\frac{dc}{dt} = 0$. Let the steady-state concentration be denoted by $c^{\\ast}$. Substituting this into the ODE gives:\n$$\n0 = k_{\\mathrm{AC}} - k_{\\mathrm{PDE}} c^{\\ast}\n$$\nSolving this algebraic equation for $c^{\\ast}$ yields:\n$$\nk_{\\mathrm{PDE}} c^{\\ast} = k_{\\mathrm{AC}} \\implies c^{\\ast} = \\frac{k_{\\mathrm{AC}}}{k_{\\mathrm{PDE}}}\n$$\n\n**Determination of the Time Constant**\nThe time constant $\\tau$ describes the characteristic time for the system to return to steady state after a perturbation. We can find this by analyzing the dynamics of a small deviation from steady state. Let $c(t) = c^{\\ast} + \\delta c(t)$, where $\\delta c(t)$ is a small perturbation.\nSubstituting this into the governing ODE:\n$$\n\\frac{d}{dt} \\left( c^{\\ast} + \\delta c(t) \\right) = k_{\\mathrm{AC}} - k_{\\mathrm{PDE}} \\left( c^{\\ast} + \\delta c(t) \\right)\n$$\nSince $c^{\\ast}$ is a constant, its derivative with respect to time is zero. The equation simplifies to:\n$$\n\\frac{d(\\delta c(t))}{dt} = k_{\\mathrm{AC}} - k_{\\mathrm{PDE}} c^{\\ast} - k_{\\mathrm{PDE}} \\delta c(t)\n$$\nFrom the steady-state condition, we know that $k_{\\mathrm{AC}} - k_{\\mathrm{PDE}} c^{\\ast} = 0$. Therefore, the equation for the perturbation becomes:\n$$\n\\frac{d(\\delta c(t))}{dt} = -k_{\\mathrm{PDE}} \\delta c(t)\n$$\nThis is a standard first-order decay equation. Its solution is of the form $\\delta c(t) = \\delta c(0) \\exp(-k_{\\mathrm{PDE}}t)$. The general form for exponential decay is typically written as $\\exp(-t/\\tau)$, where $\\tau$ is the time constant. By comparing the two forms, we can identify the time constant as:\n$$\n\\tau = \\frac{1}{k_{\\mathrm{PDE}}}\n$$\n\n**Numerical Computation**\nWe are given the values $k_{\\mathrm{AC}} = 2\\,\\mu\\mathrm{M\\,s^{-1}}$ and $k_{\\mathrm{PDE}} = 1\\,\\mathrm{s^{-1}}$.\n\nThe steady-state concentration $c^{\\ast}$ is:\n$$\nc^{\\ast} = \\frac{k_{\\mathrm{AC}}}{k_{\\mathrm{PDE}}} = \\frac{2\\,\\mu\\mathrm{M\\,s^{-1}}}{1\\,\\mathrm{s^{-1}}} = 2\\,\\mu\\mathrm{M}\n$$\nRounding to $3$ significant figures gives $c^{\\ast} = 2.00\\,\\mu\\mathrm{M}$.\n\nThe time constant $\\tau$ is:\n$$\n\\tau = \\frac{1}{k_{\\mathrm{PDE}}} = \\frac{1}{1\\,\\mathrm{s^{-1}}} = 1\\,\\mathrm{s}\n$$\nRounding to $3$ significant figures gives $\\tau = 1.00\\,\\mathrm{s}$.\n\nThe final answer is to be presented as a $1\\times 2$ row vector $[c^{\\ast}, \\tau]$. The numerical values are $2.00$ for $c^{\\ast}$ (in $\\mu\\mathrm{M}$) and $1.00$ for $\\tau$ (in $\\mathrm{s}$).", "answer": "$$\n\\boxed{\\begin{pmatrix} 2.00 & 1.00 \\end{pmatrix}}\n$$", "id": "2803640"}, {"introduction": "In real biological systems, a single GPCR can engage multiple G protein subtypes, initiating a complex web of downstream signals. A key skill for a cell biologist is to dissect these branching pathways. This advanced exercise places you in the role of an experimentalist, tasked with interpreting a set of data to unravel a receptor's signaling signature [@problem_id:2803646]. By understanding the specific molecular mechanism of Pertussis Toxin (PTX), a tool that selectively uncouples Gαi/o proteins from their receptors, you will learn how to parse which cellular responses are mediated by the PTX-sensitive pathway versus other, insensitive pathways.", "problem": "A laboratory is studying a G protein-coupled receptor (GPCR) that appears to engage multiple heterotrimeric G proteins in human embryonic kidney cells. The team co-expresses the receptor with a G protein-regulated inward-rectifier potassium channel (GIRK) to sensitively report free $\\mathrm{G}\\beta\\gamma$, and they quantify cyclic adenosine monophosphate ($[\\mathrm{cAMP}]$) by enzyme-linked immunoassay and inositol monophosphate ($\\mathrm{IP}_{1}$) accumulation as a proxy for phospholipase C beta (PLC$\\beta$) activity. They test the receptor’s agonist under four conditions.\n\nObservations:\n- In untreated cells, the agonist reduces isoproterenol-elevated $[\\mathrm{cAMP}]$ by $40\\%$, elicits a GIRK inward current of approximately $-300$ pA, and increases $\\mathrm{IP}_{1}$ by $+200$ pmol per well.\n- After overnight exposure to pertussis toxin (PTX), the agonist no longer reduces $[\\mathrm{cAMP}]$ and no longer elicits a GIRK current, but its $\\mathrm{IP}_{1}$ increase is unchanged.\n- Isoproterenol’s ability to elevate $[\\mathrm{cAMP}]$ is unchanged by PTX.\n- Expression of a PTX-insensitive $\\mathrm{G}\\alpha_i$ mutant (cysteine-to-isoleucine substitution at the conserved C-terminal site) restores the agonist-driven reduction of $[\\mathrm{cAMP}]$ and the GIRK current in PTX-treated cells.\n\nUsing only foundational principles of heterotrimeric G protein signaling—namely that GPCRs act as guanine nucleotide exchange factors to promote guanosine diphosphate (GDP) release and guanosine triphosphate (GTP) binding on $\\mathrm{G}\\alpha$, that the C-terminal tail of $\\mathrm{G}\\alpha$ is central to receptor engagement, and that covalent modification of interaction surfaces can block protein-protein coupling—select the option that best explains both:\n(i) the molecular mechanism by which PTX-catalyzed ADP-ribosylation of $\\mathrm{G}\\alpha_i$ prevents receptor coupling, and\n(ii) why PTX is a useful tool to dissect signaling pathway branch points in this experiment.\n\nA. PTX ADP-ribosylates a conserved C-terminal cysteine on GDP-bound $\\mathrm{G}\\alpha_i/\\mathrm{o}$ within the heterotrimer, disrupting the receptor–$\\mathrm{G}\\alpha$ interface so the GPCR cannot function as a guanine nucleotide exchange factor. As a result, $\\mathrm{G}\\alpha_i$ remains GDP-bound with $\\mathrm{G}\\beta\\gamma$ sequestered, abolishing both $\\mathrm{G}\\alpha_i$-mediated adenylyl cyclase inhibition and $\\mathrm{G}\\beta\\gamma$-mediated GIRK/PLC$\\beta$ signaling; PTX thus selectively removes the $\\mathrm{G}_i/\\mathrm{o}$ branch while sparing PTX-insensitive branches (for example, $\\mathrm{G}_q$-PLC$\\beta$), allowing attribution of the unchanged $\\mathrm{IP}_{1}$ response to a PTX-insensitive coupling and the lost $[\\mathrm{cAMP}]$ decrease and GIRK to $\\mathrm{G}_i/\\mathrm{o}$. Rescue by a PTX-insensitive $\\mathrm{G}\\alpha_i$ confirms causality.\nB. PTX stabilizes $\\mathrm{G}\\alpha_i$ in the GTP-bound state by inhibiting its intrinsic GTPase activity, producing persistent inhibition of adenylyl cyclase and sustained $\\mathrm{G}\\beta\\gamma$ release; PTX is therefore used to mimic constitutive $\\mathrm{G}_i$ activation and amplify GIRK and PLC$\\beta$ signaling.\nC. PTX ADP-ribosylates the GPCR’s third intracellular loop, preventing arrestin binding while preserving G protein coupling; PTX is thus used to isolate arrestin-independent G protein signaling by eliminating arrestin-mediated desensitization.\nD. PTX selectively dissociates the heterotrimer to free $\\mathrm{G}\\beta\\gamma$ while inactivating $\\mathrm{G}\\alpha_i$, thereby enhancing GIRK and PLC$\\beta$ responses even as adenylyl cyclase inhibition is lost; PTX is therefore used to test the sufficiency of $\\mathrm{G}\\beta\\gamma$ for downstream signaling.\nE. PTX directly inhibits adenylyl cyclase catalytic subunits, preventing changes in $[\\mathrm{cAMP}]$ without altering G protein coupling; PTX is therefore used to determine whether observed $[\\mathrm{cAMP}]$ changes are receptor-proximal or effector-proximal.\n\nChoose the single best option.", "solution": "The problem requires an explanation for a set of experimental observations on a G protein-coupled receptor (GPCR) based on foundational principles of heterotrimeric G protein signaling. The analysis must elucidate the molecular mechanism of pertussis toxin (PTX) and its utility as a tool in this specific experimental context.\n\nFirst, a systematic analysis of the provided data is necessary. The experiment utilizes three distinct readouts to probe the signaling pathways downstream of the receptor: cyclic adenosine monophosphate ($[\\mathrm{cAMP}]$) levels, G protein-regulated inward-rectifier potassium channel (GIRK) currents, and inositol monophosphate ($\\mathrm{IP}_{1}$) accumulation.\n\nIn the baseline condition (untreated cells), agonist stimulation of the receptor leads to three concurrent events:\n1.  A $40\\%$ reduction in isoproterenol-elevated $[\\mathrm{cAMP}]$. Isoproterenol is a known activator of $\\beta$-adrenergic receptors, which couple to the stimulatory G protein, $\\mathrm{G}_s$, thereby activating adenylyl cyclase and increasing $[\\mathrm{cAMP}]$. A reduction in this elevated $[\\mathrm{cAMP}]$ level indicates that the agonist-activated receptor couples to an inhibitory G protein, a member of the $\\mathrm{G}_i/\\mathrm{o}$ family. The $\\mathrm{G}\\alpha_i$ subunit, upon activation, inhibits most isoforms of adenylyl cyclase.\n2.  A GIRK inward current of approximately $-300$ pA. GIRK channels are Hallmark effectors of free $\\mathrm{G}\\beta\\gamma$ subunits. The release of free $\\mathrm{G}\\beta\\gamma$ occurs upon the dissociation of any heterotrimeric G protein ($\\mathrm{G}\\alpha\\beta\\gamma$) into $\\mathrm{G}\\alpha$-GTP and $\\mathrm{G}\\beta\\gamma$. This observation is consistent with the activation of a $\\mathrm{G}_i/\\mathrm{o}$ protein.\n3.  An increase of $\\mathrm{IP}_{1}$ by $+200$ pmol per well. $\\mathrm{IP}_{1}$ is a stable metabolite of inositol trisphosphate ($\\mathrm{IP}_{3}$), and its accumulation serves as a proxy for the activity of phospholipase C beta (PLC$\\beta$). PLC$\\beta$ is canonically activated by $\\mathrm{G}\\alpha$ subunits of the $\\mathrm{G}_q/\\mathrm{G}_{11}$ family. Some isoforms of PLC$\\beta$ can also be activated by $\\mathrm{G}\\beta\\gamma$ subunits, typically released from activated $\\mathrm{G}_i/\\mathrm{o}$ proteins.\n\nTherefore, in untreated cells, the receptor demonstrably couples to the $\\mathrm{G}_i/\\mathrm{o}$ pathway and also activates the PLC$\\beta$ pathway, either through $\\mathrm{G}_q/\\mathrm{G}_{11}$ or through $\\mathrm{G}\\beta\\gamma$ from $\\mathrm{G}_i/\\mathrm{o}$.\n\nNext, we analyze the effect of pertussis toxin (PTX). PTX is a bacterial toxin known to catalyze the ADP-ribosylation of a specific cysteine residue located in the C-terminal region of $\\mathrm{G}\\alpha$ subunits belonging to the $\\mathrm{G}_i/\\mathrm{o}$ family (but not $\\mathrm{G}_s$, $\\mathrm{G}_q$, or $\\mathrm{G}_{12}$). This C-terminal region is critical for the interaction between the G protein and the GPCR. By modifying this site, PTX uncouples the G protein from the receptor, preventing the receptor from acting as a guanine nucleotide exchange factor (GEF) for that G protein. The G protein is thus \"locked\" in its inactive, GDP-bound heterotrimeric state.\n\nThe observations in PTX-treated cells are:\n1.  The agonist no longer reduces $[\\mathrm{cAMP}]$. This is the direct consequence of uncoupling the receptor from $\\mathrm{G}_i$. Without activation of $\\mathrm{G}_i$, there is no $\\mathrm{G}\\alpha_i$-GTP to inhibit adenylyl cyclase.\n2.  The agonist no longer elicits a GIRK current. This demonstrates that the $\\mathrm{G}\\beta\\gamma$ subunits responsible for GIRK activation are released from a PTX-sensitive G protein, namely $\\mathrm{G}_i/\\mathrm{o}$. Since PTX prevents the activation and dissociation of the $\\mathrm{G}_i$ heterotrimer, no free $\\mathrm{G}\\beta\\gamma$ is released from this pool.\n3.  The $\\mathrm{IP}_{1}$ increase is unchanged. This is a critical result. The complete loss of $\\mathrm{G}_i/\\mathrm{o}$ signaling (evidenced by the loss of $[\\mathrm{cAMP}]$ reduction and GIRK current) has no effect on PLC$\\beta$ activation. This rules out the hypothesis that PLC$\\beta$ was being activated by $\\mathrm{G}\\beta\\gamma$ subunits released from $\\mathrm{G}_i$. The activation of PLC$\\beta$ must therefore proceed through a PTX-insensitive pathway. The canonical PTX-insensitive activator of PLC$\\beta$ is the $\\mathrm{G}_q/\\mathrm{G}_{11}$ family of G proteins. Thus, the receptor must also couple to $\\mathrm{G}_q$.\n\nThe control experiment, showing that isoproterenol's effect is unchanged by PTX, confirms that PTX's action is specific to the $\\mathrm{G}_i/\\mathrm{o}$ pathway and that it does not non-specifically poison adenylyl cyclase or the $\\mathrm{G}_s$ pathway.\n\nThe rescue experiment provides definitive proof. Expressing a $\\mathrm{G}\\alpha_i$ mutant where the target cysteine is replaced by an isoleucine (which cannot be ADP-ribosylated by PTX) restores the agonist-induced $[\\mathrm{cAMP}]$ reduction and GIRK current. This confirms that these two signaling events are indeed mediated by receptor coupling to $\\mathrm{G}\\alpha_i$.\n\nIn summary, the receptor exhibits dual coupling to both the PTX-sensitive $\\mathrm{G}_i$ pathway and the PTX-insensitive $\\mathrm{G}_q$ pathway. PTX serves as a pharmacological tool to selectively ablate the $\\mathrm{G}_i$ branch, allowing the experimenter to parse which downstream effects belong to which G protein pathway.\n\nNow, we evaluate the provided options.\n\nA. This option correctly states that PTX ADP-ribosylates a C-terminal cysteine on $\\mathrm{G}\\alpha_i/\\mathrm{o}$, preventing the GPCR from functioning as a GEF. It accurately describes the consequence: $\\mathrm{G}\\alpha_i$ remains in a GDP-bound heterotrimer, sequestering $\\mathrm{G}\\beta\\gamma$. This abolishes $\\mathrm{G}\\alpha_i$-mediated adenylyl cyclase inhibition and $\\mathrm{G}\\beta\\gamma$-mediated GIRK activation. It correctly identifies the utility of PTX as a tool to selectively remove the $\\mathrm{G}_i/\\mathrm{o}$ branch, sparing PTX-insensitive branches like $\\mathrm{G}_q$. It then correctly interprets the experimental data: the unchanged $\\mathrm{IP}_{1}$ response is attributed to a PTX-insensitive coupling (i.e., $\\mathrm{G}_q$), while the lost effects are attributed to $\\mathrm{G}_i/\\mathrm{o}$. Finally, it correctly interprets the rescue experiment as confirmation of causality. This option is a complete and accurate description of the situation.\nVerdict: **Correct**.\n\nB. This option claims PTX stabilizes the GTP-bound state of $\\mathrm{G}\\alpha_i$ by inhibiting its GTPase activity. This is the mechanism of cholera toxin on $\\mathrm{G}\\alpha_s$, not pertussis toxin on $\\mathrm{G}\\alpha_i$. The described consequence (persistent signaling) is the opposite of the experimental observation (abolished signaling).\nVerdict: **Incorrect**.\n\nC. This option incorrectly identifies the target of PTX as the GPCR's third intracellular loop. The target is the $\\mathrm{G}\\alpha_i$ subunit. The described function of isolating arrestin-independent signaling is unrelated to the known mechanism of PTX or the experimental data presented.\nVerdict: **Incorrect**.\n\nD. This option claims PTX dissociates the heterotrimer to free $\\mathrm{G}\\beta\\gamma$. This is incorrect; PTX prevents dissociation by locking the G protein in the inactive, coupled state. The predicted outcome of enhanced GIRK response is directly contradicted by the data, which show the GIRK current is abolished.\nVerdict: **Incorrect**.\n\nE. This option suggests PTX directly inhibits adenylyl cyclase. This is refuted by the control experiment showing that isoproterenol's (a $\\mathrm{G}_s$-mediated activator) effect on $[\\mathrm{cAMP}]$ is unchanged by PTX. If adenylyl cyclase were directly inhibited, its activation by any means would be blocked. Furthermore, this option fails to explain the loss of the GIRK current.\nVerdict: **Incorrect**.\n\nBased on a rigorous analysis of the experimental data and foundational principles, Option A is the only choice that provides an entirely correct and comprehensive explanation.", "answer": "$$\\boxed{A}$$", "id": "2803646"}]}